Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study
Vaccine (2022) - Comments
doi: 10.1016/j.vaccine.2022.06.032  issn: 0264-410x  pubmed: 35738968  issn: 1873-2518 

Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Yokokawa Shibata, Naomi M. Seki, Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, Kenji Igarashi, Mari Ariyasu